Results 91 to 100 of about 878,591 (299)

Myelodysplastic syndrome and extracapillary glomerulonephritis: is there a link?

open access: yesAfrican Journal of Nephrology, 2012
Introduction: The association of myelodysplastic syndrome and extracapillary glomerulonephritis is exceptional. Only two other cases have been reported.
MA Hamzi   +5 more
doaj   +1 more source

Sonogenetics Nanomedicine Activates the cGAS‐STING Pathway for Immunotherapy of Triple‐Negative Breast Cancer

open access: yesAdvanced Science, EarlyView.
A HER3‐targeted sonogenetic lipid nanoparticle platform is developed for triple‐negative breast cancer therapy. An AI‐designed miniprotein inhibits HER3 signaling, while TRPV4 and NFAT‐responsive IL‐15 plasmids enable ultrasound‐controlled calcium signaling and cytokine expression. The system induces Ca2+ overload, ROS generation, mitochondrial damage,
Junya Song   +6 more
wiley   +1 more source

Super high-flux dialyzers improve survival in patients on hemodialysis: a cohort study of the Japanese Society for Dialysis Therapy (JSDT) Renal Data Registry

open access: yesRenal Replacement Therapy
Background In Japan dialyzers are classified as type I, II, III, IV, or V on the basis of the β 2-microglobulin clearance. In 2023, Type V dialyzers were defined as super high-flux membrane dialyzers.
Masanori Abe   +5 more
doaj   +1 more source

The Multidisciplinary Approach to Renal Denervation: Current Evidences and Open Questions [PDF]

open access: yesEuropean Medical Journal Nephrology, 2014
Renal denervation (RD) is a new clinical procedure which aims to treat resistant hypertensive patients. As with every new technology introduced into the clinical setting, many aspects were not explored sufficiently in order to be implemented into routine
Sara Samoni   +10 more
doaj  

Reversible Fluindione-Induced Chronic Interstitial Nephritis

open access: yesCase Reports in Nephrology, 2016
Fluindione is well known to induce acute drug-induced interstitial nephritis (IN). Most cases occurred soon after the onset of treatment. We report a unique case of severe subacute fluindione-induced IN diagnosed 2 years after the treatment was begun ...
Thomas Crepin   +5 more
doaj   +1 more source

Modulation of the TGF‐β/Smad Signaling Pathway by a Bioactive Oxidized Polygonati Rhizoma Polysaccharide Crosslinked Chitosan Hydrogel as Therapeutic Carrier for Parkinson's Disease Treatment

open access: yesAdvanced Science, EarlyView.
An injectable, self‐healing COPRP hydrogel integrates structurally defined oxidized Polygonati rhizoma polysaccharide with carboxymethyl chitosan through dynamic Schiff‐base crosslinking. The bioactive matrix scavenges reactive oxygen species, suppresses neuroinflammation, protects dopaminergic neurons, and supports sustained levodopa release.
Peng Dai   +10 more
wiley   +1 more source

Stigma and related factors among renal dialysis patients in China. [PDF]

open access: yesFront Psychiatry, 2023
Li B, Liu D, Zhang Y, Xue P.
europepmc   +1 more source

Intermittent infusion hemodiafiltration is associated with improved survival compared to hemodialysis

open access: yesRenal Replacement Therapy
Background Approximately 16.4% of patients on hemodialysis (HD) in Japan are treated with intermittent infusion hemodiafiltration (I-HDF). However, large-scale data on clinical outcomes with this modality are lacking.
Masanori Abe   +4 more
doaj   +1 more source

Epidermolysis bullosa: A rare challenge for peritoneal dialysis nurses

open access: yes, 2013
Epidermolysis bullosa is a genetic skin disorder characterised by blister formation in response to minimal trauma or friction. Our renal service was required to provide peritoneal dialysis (PD) for a young lady suffering from this rare disease and this
Cuesta, C, Blow, T, Tranter, SA
core  

TROP2‐Targeting Chimeras (TRTACs) for Tumor Cell‐Selective Membrane Protein Degradation and Enhanced Drug Delivery

open access: yesAdvanced Science, EarlyView.
TROP2 is identified as a novel tumor‐selective lysosomal‐targeting receptor with established clinical relevance. TROP2‐targeting chimeras (TRTACs) are developed by genetically fusing a TROP2‐binding nanobody to nanobodies against specific target proteins.
Luping Chen   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy